Litigation Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)
✉ Email this page to a colleague
Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-09-22 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 6,211,244; 6,316,460; 9,375,405 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
Biologic Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-09-22 | 1 | Complaint | action for infringement of U.S. Patent No. 9,375,405 (the “‘405 patent”). 7. This action… THE PATENT-IN-SUIT 14. United States Patent No. 9,375,405, entitled “Rapid…United States Patent and Trademark Office (“PTO”) on June 28, 2016. A copy of the ‘405 patent is attached…15. The ‘405 patent is assigned to Amgen and Amgen is the owner of the ‘405 patent. …405 patent when Aurobindo Ltd notified Amgen of its Paragraph IV Certification of the ‘405 patent. | External link to document |
| 2016-12-15 | 14 | Status Report | undergo parathyroidectomy. U.S. Patent No. 9,375,405 (the “’405 patent”) is listed in Approved Drug Products…‘405 patent invalid. 2. A judgment that no asserted claim of the ‘405 patent is infringed…Substance of the Actions These are Hatch-Waxman patent infringement actions relating to cinacalcet hydrochloride…United States prior to the expiration of the ’405 patent. By letter dated August 5, 2016, Aurobindo notified…United States prior to the expiration of the ’405 patent. By letter dated August 3, 2016, Micro Labs notified | External link to document |
| 2017-07-19 | 186 | Memorandum and Order | ORDER Construing the Terms of U.S. Patent No. 9,375,405. Signed by Judge Gregory M. Sleet on 7/19…September 2016 1:16-cv-00853-MSG 830 Patent None District Court, D. Delaware | External link to document |
| 2017-09-26 | 228 | Notice of Service | Ph.D. Regarding Non-Infringement of U.S. Patent No. 9,375,405 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals…September 2016 1:16-cv-00853-MSG 830 Patent None District Court, D. Delaware | External link to document |
| 2017-09-26 | 230 | Notice of Service | Roush, Ph.D. Regarding the Validity of U.S. Patent No. 9,375,405; (3) Rebuttal Expert Report of Dr. Martyn…C. Davies in Support of Validity of U.S. Patent No. 9,375,405; and (4) Rebuttal Expert Report of David…September 2016 1:16-cv-00853-MSG 830 Patent None District Court, D. Delaware | External link to document |
| 2017-11-02 | 252 | Consent Judgment | Amgen's United States Patent Number 9,375,405, (the "Amgen Patent") is enforceable and…, Defendants shall not dispute that the Amgen Patent is enforceable and valid. 5. …Settlement Agreement would infringe the Amgen Patent. …successors and assigns, is enjoined under the '405 patent, including any extensions and/or additional periods… or becomes entitled, from infringing the Amgen Patent, on its own part or through any Affiliate, by | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
